Benevolent AI (Benevolent AI) Debt-to-Revenue : 0.58 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Benevolent AI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.17 Mil. Benevolent AI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.84 Mil. Benevolent AI's annualized Revenue for the quarter that ended in Dec. 2023 was $10.30 Mil. Benevolent AI's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.58.

Benevolent AI Debt-to-Revenue Historical Data

The historical data trend for Benevolent AI's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Debt-to-Revenue Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

2.48

1.50

1.90

0.70

0.65

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial				0.74	0.43	0.32	0.30	0.58

Competitive Comparison of Benevolent AI's Debt-to-Revenue

For the Biotechnology subindustry, Benevolent AI's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Debt-to-Revenue falls into.

Benevolent AI Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Benevolent AI's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.171	+	4.839)	/	9.28
	=	0.65

Benevolent AI's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.171	+	4.839)	/	10.3
	=	0.58

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Benevolent AI Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.